Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study
2019 · Leukemia · 447 citations
https://doi.org/10.1038/s41375-019-0602-x
P
Paul M. Barr
City of Hope(US)
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
451
Papers
16.4K
Citations
53
h-index
153
i10-index
Paul M. Barr is an academic researcher from City of Hope. The author has contributed to research in topics: Chronic Lymphocytic Leukemia Research & Lymphoma Diagnosis and Treatment & Chronic Myeloid Leukemia Treatments. The author has an h-index of 53, co-authored 384 publications.
ORCID: 0000-0002-9733-401XPapers by this author
worksLong-Term Studies Assessing Outcomes of Ibrutinib Therapy in Patients With Del(11q) Chronic Lymphocytic Leukemia
2019 · Clinical Lymphoma Myeloma & Leukemia · 45 citations
https://doi.org/10.1016/j.clml.2019.07.004
Final Analysis of the RESONATE-2 Study: Up to 10 Years of Follow-Up of First-Line Ibrutinib Treatment in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
2024 · Clinical Lymphoma Myeloma & Leukemia · 8 citations
https://doi.org/10.1016/s2152-2650(24)00565-2
Outcomes in High-Risk Subgroups After Fixed-Duration Ibrutinib (Ibr) + Venetoclax (Ven) for Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Up to 5.5 Years of Follow-Up in the Phase 2 CAPTIVATE Study
2024 · Clinical Lymphoma Myeloma & Leukemia · 2 citations
https://doi.org/10.1016/s2152-2650(24)00564-0
CLL-057 Outcomes in High-Risk Subgroups After Fixed-Duration Ibrutinib (Ibr) + Venetoclax (Ven) for Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Up to 5.5 Years of Follow-Up in the Phase 2 CAPTIVATE Study
2024 · Clinical Lymphoma Myeloma & Leukemia · 1 citations
https://doi.org/10.1016/s2152-2650(24)01258-8
PCR91 Patient Reported Outcomes in BRUIN CLL-321: A Phase 3 Trial of Pirtobrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
2025 · Value in Health · 1 citations
https://doi.org/10.1016/j.jval.2025.04.1411
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat